Table 1 Results of primary outcomes analysis showing estimated odds ratios for the association between (for each cytokine) exposure and the risk of CRPS, where exposure is defined as being above the 80th centile for controls. Intra-assay coefficients of variation (CV) are provided for each cytokine. OR = Odds ratio; CI = confidence interval; IL-1β = interleukin-1 beta; IL-10 = interleukin-10; IFN-α = interferon alpha; IL-6 = interleukin-6; IL-12 = interleukin-12; RANTES = Regulated on Activation, Normal T Cell Expressed and Secreted; IL-13 = interleukin-13; IL-15 = interleukin-15; IL-17 = interleukin-17; MIP-1α = macrophage inflammatory protein-1 alpha; GM-CSF = granulocyte-macrophage colony stimulating-factor; MIP-1β = macrophage inflammatory protein-1 alpha; MCP-1 = monocyte chemoattractant protein-1; IL-5 = interleukin-5; IFN-γ = interferon gamma; TNF-α = tumor necrosis factor alpha; IL-1Ra = interleukin 1 receptor antagonist; IL-2 = interleukin-2; IL-7 = interleukin-7; IP-10 = interferon gamma-induced protein-10; IL-2r = interleukin-2 receptor; MIG = monokine induced by interferon-gamma; IL-4 = interleukin-4; IL-8 = interleukin-8.

From: Post-fracture serum cytokine levels are not associated with a later diagnosis of complex regional pain syndrome: a case-control study nested in a prospective cohort study